A comparative study of ferric carboxy maltose versus iron sucrose for iron deficiency anaemia in pregnancy


  • Nikitha James Father Muller Medical College, Karnataka, India
  • Ramalingappa C. Antartani Karnataka Institute of Medical Sciences, Hubli, Karnataka, India
  • Neha Anu James Father Muller Medical College, Karnataka, India




Anaemia, Ferric carboxy maltose, Iron sucrose, Iron deficiency


Background: Anaemia is a major contributor to maternal morbidity and mortality worldwide. Ferric carboxy maltose is a novel iron preparation which can treat anaemia faster and more effectively. Thus, this study aimed to evaluate the efficacy and safety of FCM in pregnancy and also to compare the same with Iron sucrose in pregnancy.

Methods: This was a Prospective, Hospital based, Comparative study performed on 120 women who attended the department of obstetrics and gynaecology at KIMS, Hubli for a duration of one and a half years (2017-18). The patients received either FCM or Iron sucrose, with 60 participants in each group.

Results: Among 120 subjects, 75% of the patients had microcytic, hypochromic anaemia, 1.4% had dimorphic anaemia.38.33% of patients had moderate anaemia (Hb 6-7.9g/dl). After FCM infusion, rise in Hb at 2 weeks was 1.5g/dl and at 4 weeks was 2.9 g/dl. Serum ferritin levels raised by 36.7 and 63.1 mcg/l at 2 and 4 weeks with FCM respectively. On comparison with Iron sucrose, the Hb rise was statistically better with FCM at 4 weeks, whereas the ferritin levels were significantly improved with FCM at both 2 and 4 weeks after treatment. Side effects in mild form occurred in 7.5% of the subjects.

Conclusions: FCM is a safe, effective alternative to other parenteral iron therapies, offering faster correction of anaemia and iron replenishment. Its use in pregnancy will significantly reduce the burden of maternal mortality and morbidity.



Garg R, Nigam A, Agrawal P, Nigam A, Agrawal R. Iron Carboxymaltose:A Safe And Effective Molecule To Combat Anemia In Pregnancy. Int J Curr Res Aca Rev. 2016;4(2):124-30.

Ralston S, Penman ID, Strachan MW, Hobson RP, Britton R, Davidson S. Principles and practice of medicine. 23rd ed. Edinburgh: Elsevier; 2018.

Park K. Textbook of preventive and social medicine. 24th ed. India: Bhanot publishers; 2017.

The work of WHO,1980-1981:biennial report of the Director-General to the World Health Assembly and to the United Nations. Available at: http://www.who.int/ iris/handle/10665/204369. Accessed on 4 September 2018.

Sixth report on the world health situation: part 1 global analysis, part 2, review by country and area. Available at: http://www.who.int/iris/handle/10665/44199. Accessed on 4 September 2018.

Jain G, Palaria UA, Jhas K. Intravenous Iron in Postpartum Anemia. J Obstet Gynecol India. 2013; 63(1):45-8.

Kharde PS, Bangal VB, Panicker KK. Comparative study of intravenous iron sucrose versus oral iron therapy in iron deficiency anemia during postpartum period. Int J Biomed Adv Res. 2012;3:4-10.

Bodnar LM, Siega-Riz AM, Miller WC, Cogswell ME, McDonald T. Who should be screened for postpartum anemia?An evaluation of current recommendations. Am J Epidemio. 2002;156:903-12.

Prevalence of anaemia in pregnancy. Available at: http://rchiips.org/nfhs/report.shtml. Accessed on 4 September 2018.

Prevalence of anaemia in pregnancy. Available at: http://rchiips.org/nfhs/factsheet_nfhs-4html. Accessed on 4 September 2018.

Breymann C, Milman N, Mezzacasa A, Bernard R, Dudenhausen J. Ferric carboxymaltose vs. oral iron in the treatment of pregnant women with iron deficiency anemia:an international open-label, randomized controlled trial (FER-ASAP). J Perinat Med. 2016; 45(4):443-53.

Shah S, Swapna K. A comparative study of efficacy and safety of intravenous ferric carboxymaltose versus intravenous iron sucrose in the treatment of iron deficiency anaemia in pregnancy. IOSR-JDMS. 2018; 17(9):13-7.

Shim JY, Kim MY, KIM YJ, Lee Y, Lee JJ, Jun JK et al. Efficacy and safety of ferric carboxymaltose versus ferrous sulfate for iron deficiency anemia during pregnancy:a subgroup analysis of Korean women. BMC Preg Childbirth. 2018;18:349.

Christoph P, Schuller C, Studer H, Irion O, Martinez B, Tejada D, et al. Intraavenous Iron Treatment In Pregnancy:Comparison Of High-Dose Ferric Carboxymaltose vs. Iron Sucrose. J Perinat Med. 2012; 40(5):469-74.

Patel J, Patel K, Patel J, Sharma A, Date SK. Comparison of intravenous iron sucrose and ferric carboxymaltose therapy in iron deficiency anemia in pregnancy and postpartum period. J Pharma Sci Biosci Res. 2015;5(3):239-43.

Pels A, Ganzevoort W. Safety and efficacy of feric carboxymaltose in anemic pregnant women: a retrospective case control study. Obstet Gynaecol Int. 2015;24:2015.

Mishra V, Chaudary S, Gandhi K, Sharma U, Patel U. Study of intravenous ferric carboxy maltose in iron deficiency anemia during pregnancy and post partum period-safety and efficacy. Indian J Obstet Gynaecol Res. 2015;2(2):69-72.

Froessler B, Collingwood J, Hodyl NA, Dekker G.Intravenous ferric carboxy maltose for anaemia in pregnancy. BMC Preg Childbirth. 2014;14:115.

Rodrigues RA, Montero MG, Aporta JP, Luque CG, Mayor AC, Ruiz JA, et al. Retrospective case reports of anemic pregnant women receiving intravenous ferric carboxymaltose:experience from a tertiary hospital in Spain. Obstet Gynecol Int. 2016;98:1-5.

Friedrisch JR, Cancado RD. Intravenous ferric carboxymaltose for the treatment of iron deficiency anemia. Brazil J Hematol Hemother. 2015;37(6):400-5.

Bregman DB, Goodnough LT. Experiance with intravenous ferric carboxymaltose in patients with iron deficiency anemia. Ther Adv Hematol. 2014;5(2):48-60.

US Food and Drug Administration Center for Drug Evaluation and Research. Available at: http://www.accessdata.fda.gov/drugsatfda.docs/nda/2013/203565Orig1s000MedR.pdf. Accessed on 4 September 2018.

Breymann C, Gliga F, Bejenariu C, Strizhova N. Comparative efficacy and safety of intravenous ferric carboxymaltose in the treatment of postpartum iron deficiency anemia. Int J Gynaecol Obstet. 2008;101: 67-73.






Original Research Articles